Navigation Links
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Date:6/17/2011

e" of the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2011 ("2011 Form 10-K");

(10) the two agreements between the Company and the Office of Inspector General of the U.S. Department of Health and Human Services ("HHS OIG") pertaining to the exclusion of our former chief executive officer from participation in federal healthcare programs and pertaining to the dissolution of our ETHEX subsidiary, in order to resolve the risk of potential exclusion of our Company, as more fully described in Part I, Item 1—"Business—(b)Significant Developments—Agreements with HHS OIG" of the Company's 2011 Form 10-K;

(11) the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 1—"Description of Business—Plea Agreement with the U.S. Department of Justice" of  the Notes to the Consolidated Financial Statements included in the  Company's 2011 Form 10-K;

(12) changes in the current and future business environment, including interest rates and capital and consumer spending;

(13) the availability of raw materials and/or products, including Makena™ and Evamist®, manufactured for the Company under contract manufacturing agreements with third parties;

(14) the regulatory environment, including legislative, governmental or regulatory agency and judicial actions and changes in applicable laws or regulations, including the risk of obtaining necessary state licenses in a timely manner;

(15) fluctuations in revenues;

(16) the difficulty of predicting the pattern of inventory movements by the Company's customers;

(17) risks that the Company may not ultimately prevail in litigation, including product liabili
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... -Submission initiates 90-day review period-, SOUTH SAN ... EXEL ) today announced that the company has,submitted ... GlaxoSmithKline,(GSK). As announced in August 2007, GSK requested ... reaches proof-of-concept as defined under the,product development and ...
... Sept. 13 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for ... that Malvina Laudicina has,joined Cadence,s management team ... She will lead the regulatory and quality ...
... CAMBRIDGE, Mass., Sept. 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... the Merrill Lynch Global Pharmaceutical, Biotech and Medtech ... by visiting the Investors section,of the Company,s website, ... ) The presentation will include an overview ...
Cached Biology Technology:Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance 2Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance 3Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation 2
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... a relatively short-term hearing deprivation during childhood may lead to ... The research, published by Cell Press in the March 11 ... like the visual cortex, development of the auditory cortex is ... just the right time. It is well established ...
... sequence exploration on nine BACs of giant panda with ... new genes and repeats were predicted, which greatly fills ... addition, the nine sequences assembled based on traditional phrap ... novo assembly accuracy of the whole genome shotgun sequencing ...
... -- A study of extinction patterns of 25 large mammal ... new areas, and interconnecting them will be necessary for many ... team of researchers from the United States and India, appears ... journal, Proceedings of the Royal Society B . ...
Cached Biology News:Research reveals that temporary hearing deprivation can lead to 'lazy ear' 2Sequencing, annotation and comparative analysis of nine BACs of giant panda (Ailuropoda melanoleuca) 2Large mammals need protected areas, forest cover in India 2
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead, 2 g. Category: Leadseeker Beads....
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
... Insect Cell Medium is optimized for serum-free ... Cells. In this protein-free medium, Sf9 cultures ... 107 cells/ml with viabilities above 95%. This ... where color from X-gluc staining of pBACgus ...
Biology Products: